Symbols / FBRX
FBRX Chart
About
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 360.40M |
| Enterprise Value | 263.60M | Income | -51.74M | Sales | — |
| Book/sh | 4.72 | Cash/sh | 7.46 | Dividend Yield | — |
| Payout | 0.00% | Employees | 16 | IPO | — |
| P/E | — | Forward P/E | -8.02 | PEG | — |
| P/S | — | P/B | 6.10 | P/C | — |
| EV/EBITDA | -4.94 | EV/Sales | — | Quick Ratio | 7.23 |
| Current Ratio | 7.34 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.08 | EPS next Y | -3.59 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 09:00 | ROA | -58.07% |
| ROE | -110.72% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 12.53M |
| Shs Float | 6.64M | Short Float | 6.51% | Short Ratio | 3.18 |
| Short Interest | — | 52W High | 35.62 | 52W Low | 4.90 |
| Beta | 3.24 | Avg Volume | 189.78K | Volume | 8.57K |
| Target Price | $63.75 | Recom | Strong_buy | Prev Close | $28.50 |
| Price | $28.77 | Change | 0.95% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$63.75
Mean price target
2. Current target
$28.87
Latest analyst target
3. DCF / Fair value
$-35.18
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$28.87
Low
$54.00
High
$75.00
Mean
$63.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-25 | init | Evercore ISI Group | — → Outperform | $65 |
| 2025-11-17 | main | Chardan Capital | Buy → Buy | $61 |
| 2025-08-18 | init | Guggenheim | — → Buy | $75 |
| 2025-08-15 | main | Chardan Capital | Buy → Buy | $61 |
| 2025-06-24 | main | Chardan Capital | Buy → Buy | $61 |
| 2025-04-01 | main | Chardan Capital | Buy → Buy | $61 |
| 2025-01-21 | init | TD Cowen | — → Buy | — |
| 2024-12-04 | main | Chardan Capital | Buy → Buy | $64 |
| 2024-11-15 | main | Chardan Capital | Buy → Buy | $64 |
| 2024-08-19 | main | Chardan Capital | Buy → Buy | $3 |
| 2024-05-30 | init | Brookline Capital | — → Buy | $4 |
| 2024-04-08 | up | Ladenburg Thalmann | Neutral → Buy | $3 |
| 2021-09-20 | up | Chardan Capital | Sell → Neutral | $4 |
| 2021-09-03 | down | Brookline Capital | Buy → Hold | — |
| 2021-09-03 | down | Chardan Capital | Buy → Sell | $4 |
| 2021-09-03 | down | Ladenburg Thalmann | Buy → Neutral | — |
| 2021-09-03 | down | B. Riley Securities | Buy → Neutral | $3 |
| 2021-09-03 | down | Truist Securities | Buy → Hold | — |
| 2021-05-14 | init | B. Riley Securities | — → Buy | $73 |
| 2021-03-26 | init | Citigroup | — → Buy | $75 |
- Price-Driven Insight from (FBRX) for Rule-Based Strategy - Stock Traders Daily hu, 19 Feb 2026 22
- Forte Biosciences chief lines up Guggenheim, TD Cowen, Barclays talks - Stock Titan Mon, 09 Feb 2026 08
- $FBRX stock is up 22% today. Here's what we see in our data. - Quiver Quantitative Mon, 12 Jan 2026 08
- We're Not Very Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate - simplywall.st ue, 11 Nov 2025 08
- Forte Biosciences (FBRX) Price Target Increased by 16.98% to 53.30 - Nasdaq ue, 30 Sep 2025 07
- Is Forte Biosciences Positioned For More Gains Ahead Of 2026 Clinical Readouts? - RTTNews hu, 18 Dec 2025 08
- New Forte Biosciences hire receives options for 75,000 shares - Stock Titan Mon, 22 Dec 2025 08
- Evercore ISI initiates coverage on Forte Biosciences stock with Outperform rating - Investing.com ue, 25 Nov 2025 08
- Institutional investors may adopt severe steps after Forte Biosciences, Inc.'s (NASDAQ:FBRX) latest 15% drop adds to a year losses - simplywall.st Sat, 03 Jan 2026 08
- New Analyst Forecast: $FBRX Given $65.0 Price Target - Quiver Quantitative ue, 25 Nov 2025 08
- Forte Biosciences Prices $75 Mln Public Offering Of Common Stock And Pre-Funded Warrants - Nasdaq Wed, 25 Jun 2025 07
- Forte Biosciences (NASDAQ: FBRX) expects 3 FB102 readouts in 2026 after IND opens - Stock Titan Fri, 14 Nov 2025 08
- (FBRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily Wed, 28 Jan 2026 08
- Monday 1/5 Insider Buying Report: LTC, FBRX - Nasdaq Mon, 05 Jan 2026 08
- Forte Biosciences Public Offering: 4 Major Banks Lead Autoimmune Drug Developer's Stock Sale - Stock Titan ue, 24 Jun 2025 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 375 | — | — | RILEY ANTONY A | Chief Financial Officer | — | 2025-12-31 00:00:00 | D | nan |
| 1 | 1250 | — | — | WAGNER PAUL A | Chief Executive Officer | — | 2025-12-31 00:00:00 | D | nan |
| 2 | 9680 | — | Purchase at price 26.33 per share. | RILEY ANTONY A | Chief Financial Officer | — | 2025-12-30 00:00:00 | D | 254833.0 |
| 3 | 375 | — | — | RILEY ANTONY A | Chief Financial Officer | — | 2025-10-01 00:00:00 | D | nan |
| 4 | 1250 | — | — | WAGNER PAUL A | Chief Executive Officer | — | 2025-10-01 00:00:00 | D | nan |
| 5 | 375 | — | — | RILEY ANTONY A | Chief Financial Officer | — | 2025-07-01 00:00:00 | D | nan |
| 6 | 1250 | — | — | WAGNER PAUL A | Chief Executive Officer | — | 2025-07-01 00:00:00 | D | nan |
| 7 | 375 | — | — | RILEY ANTONY A | Chief Financial Officer | — | 2025-04-01 00:00:00 | D | nan |
| 8 | 1250 | — | — | WAGNER PAUL A | Chief Executive Officer | — | 2025-04-01 00:00:00 | D | nan |
| 9 | 375 | — | — | RILEY ANTONY A | Chief Financial Officer | — | 2024-12-31 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -36.56M | -32.48M | -13.90M | -21.45M |
| TotalUnusualItems | 0.00 | |||
| TotalUnusualItemsExcludingGoodwill | 0.00 | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -35.48M | -31.48M | -13.88M | -21.71M |
| ReconciledDepreciation | 39.00K | 9.00K | 0.00 | 36.00K |
| EBITDA | -36.56M | -32.48M | -13.90M | -21.45M |
| EBIT | -36.60M | -32.49M | -13.90M | -21.49M |
| NetInterestIncome | 1.31M | 1.12M | 162.00K | |
| InterestIncome | 1.31M | 1.12M | 162.00K | |
| NormalizedIncome | -35.48M | -31.48M | -13.88M | -21.71M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -35.48M | -31.48M | -13.88M | -21.71M |
| TotalExpenses | 36.60M | 32.49M | 13.90M | 21.49M |
| TotalOperatingIncomeAsReported | -36.60M | -32.49M | -13.90M | -21.49M |
| DilutedAverageShares | 2.92M | 1.26M | 695.34K | 558.71K |
| BasicAverageShares | 2.92M | 1.26M | 695.34K | 558.71K |
| DilutedEPS | -12.17 | -24.92 | -20.00 | -38.75 |
| BasicEPS | -12.17 | -24.92 | -20.00 | -38.75 |
| DilutedNIAvailtoComStockholders | -35.48M | -31.48M | -13.88M | -21.71M |
| NetIncomeCommonStockholders | -35.48M | -31.48M | -13.88M | -21.71M |
| NetIncome | -35.48M | -31.48M | -13.88M | -21.71M |
| NetIncomeIncludingNoncontrollingInterests | -35.48M | -31.48M | -13.88M | -21.71M |
| NetIncomeContinuousOperations | -35.48M | -31.48M | -13.88M | -21.71M |
| PretaxIncome | -35.48M | -31.48M | -13.88M | -21.71M |
| OtherIncomeExpense | -190.00K | -114.00K | -145.00K | -222.00K |
| OtherNonOperatingIncomeExpenses | -190.00K | -114.00K | -145.00K | -222.00K |
| SpecialIncomeCharges | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 1.31M | 1.12M | 162.00K | |
| InterestIncomeNonOperating | 1.31M | 1.12M | 162.00K | |
| OperatingIncome | -36.60M | -32.49M | -13.90M | -21.49M |
| OperatingExpense | 36.60M | 32.49M | 13.90M | 21.49M |
| ResearchAndDevelopment | 21.19M | 21.86M | 5.59M | 13.85M |
| SellingGeneralAndAdministration | 15.41M | 10.62M | 8.30M | 7.63M |
| GeneralAndAdministrativeExpense | 15.41M | 10.62M | 8.30M | 7.63M |
| OtherGandA | 15.41M | 10.62M | 8.30M | 7.63M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 6.39M | 1.45M | 840.00K | 590.18K |
| ShareIssued | 6.39M | 1.45M | 840.00K | 590.18K |
| TangibleBookValue | 52.48M | 35.31M | 38.82M | 41.55M |
| InvestedCapital | 52.48M | 35.31M | 38.82M | 41.55M |
| WorkingCapital | 52.27M | 34.66M | 38.33M | 40.76M |
| NetTangibleAssets | 52.48M | 35.31M | 38.82M | 41.55M |
| CommonStockEquity | 52.48M | 35.31M | 38.82M | 41.55M |
| TotalCapitalization | 52.48M | 35.31M | 38.82M | 41.55M |
| TotalEquityGrossMinorityInterest | 52.48M | 35.31M | 38.82M | 41.55M |
| StockholdersEquity | 52.48M | 35.31M | 38.82M | 41.55M |
| GainsLossesNotAffectingRetainedEarnings | 11.00K | 4.00K | 0.00 | |
| OtherEquityAdjustments | 11.00K | 4.00K | ||
| RetainedEarnings | -154.00M | -118.52M | -87.04M | -73.17M |
| AdditionalPaidInCapital | 206.46M | 153.83M | 125.84M | 114.70M |
| CapitalStock | 6.00K | 1.00K | 21.00K | 15.00K |
| CommonStock | 6.00K | 1.00K | 21.00K | 15.00K |
| TotalLiabilitiesNetMinorityInterest | 9.08M | 3.67M | 3.18M | 1.76M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| CurrentLiabilities | 9.08M | 3.67M | 3.18M | 1.76M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.55M | 947.00K | 890.00K | 681.00K |
| PayablesAndAccruedExpenses | 7.53M | 2.72M | 2.29M | 1.08M |
| CurrentAccruedExpenses | 2.65M | 1.29M | 1.14M | 131.00K |
| Payables | 4.88M | 1.42M | 1.15M | 946.00K |
| AccountsPayable | 4.88M | 1.42M | 1.15M | 946.00K |
| TotalAssets | 61.56M | 38.98M | 42.00M | 43.31M |
| TotalNonCurrentAssets | 215.00K | 653.00K | 486.00K | 786.00K |
| OtherNonCurrentAssets | 51.00K | 53.00K | 13.00K | 13.00K |
| NonCurrentPrepaidAssets | 87.00K | 491.00K | 473.00K | 773.00K |
| NetPPE | 77.00K | 109.00K | 0.00 | 0.00 |
| AccumulatedDepreciation | -48.00K | -9.00K | 0.00 | |
| GrossPPE | 125.00K | 118.00K | 0.00 | |
| OtherProperties | 107.00K | 100.00K | ||
| MachineryFurnitureEquipment | 18.00K | 18.00K | 0.00 | |
| CurrentAssets | 61.35M | 38.33M | 41.51M | 42.52M |
| OtherCurrentAssets | 336.00K | 165.00K | 70.00K | 89.00K |
| PrepaidAssets | 2.65M | 1.04M | 341.00K | 387.00K |
| CashCashEquivalentsAndShortTermInvestments | 58.37M | 37.12M | 41.10M | 42.04M |
| OtherShortTermInvestments | 36.12M | 25.16M | ||
| CashAndCashEquivalents | 22.24M | 11.96M | 41.10M | 42.04M |
| CashEquivalents | 20.78M | 5.69M | 5.06M | |
| CashFinancial | 1.46M | 6.28M | 36.04M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -30.78M | -28.79M | -8.19M | -16.68M |
| RepurchaseOfCapitalStock | -1.00K | 0.00 | ||
| IssuanceOfCapitalStock | 53.00M | 25.00M | 7.23M | 0.00 |
| CapitalExpenditure | -37.00K | -88.00K | ||
| EndCashPosition | 22.24M | 37.12M | 41.10M | 42.04M |
| BeginningCashPosition | 37.12M | 41.10M | 42.04M | 58.77M |
| ChangesInCash | -14.88M | -3.98M | -944.00K | -16.72M |
| FinancingCashFlow | 51.86M | 24.68M | 7.24M | -44.00K |
| CashFlowFromContinuingFinancingActivities | 51.86M | 24.68M | 7.24M | -44.00K |
| NetOtherFinancingCharges | -1.16M | -332.00K | -106.00K | |
| ProceedsFromStockOptionExercised | 14.00K | 16.00K | 12.00K | 62.00K |
| NetCommonStockIssuance | 53.00M | 25.00M | 7.23M | 0.00 |
| CommonStockPayments | -1.00K | 0.00 | ||
| CommonStockIssuance | 53.00M | 25.00M | 7.23M | 0.00 |
| InvestingCashFlow | -35.99M | 47.00K | 0.00 | 0.00 |
| CashFlowFromContinuingInvestingActivities | -35.99M | 47.00K | 0.00 | 0.00 |
| NetInvestmentPurchaseAndSale | -35.96M | 135.00K | 0.00 | |
| SaleOfInvestment | 0.00 | 10.10M | 0.00 | |
| PurchaseOfInvestment | -35.96M | -9.96M | 0.00 | |
| NetPPEPurchaseAndSale | -37.00K | -88.00K | 0.00 | |
| PurchaseOfPPE | -37.00K | -88.00K | 0.00 | |
| OperatingCashFlow | -30.75M | -28.71M | -8.19M | -16.68M |
| CashFlowFromContinuingOperatingActivities | -30.75M | -28.71M | -8.19M | -16.68M |
| ChangeInWorkingCapital | 1.76M | -392.00K | 1.68M | 720.00K |
| ChangeInPayablesAndAccruedExpense | 3.13M | 457.00K | 1.42M | -501.00K |
| ChangeInAccruedExpense | 109.00K | 186.00K | 1.21M | -207.00K |
| ChangeInPayable | 3.02M | 271.00K | 207.00K | -294.00K |
| ChangeInAccountPayable | 3.02M | 271.00K | 207.00K | -294.00K |
| ChangeInPrepaidAssets | -1.37M | -849.00K | 258.00K | 1.22M |
| OtherNonCashItems | -158.00K | -131.00K | ||
| StockBasedCompensation | 3.10M | 3.28M | 4.01M | 4.21M |
| AssetImpairmentCharge | 0.00 | 61.00K | ||
| DepreciationAmortizationDepletion | 39.00K | 9.00K | 0.00 | 36.00K |
| DepreciationAndAmortization | 39.00K | 9.00K | 0.00 | 36.00K |
| Depreciation | 39.00K | 9.00K | 0.00 | 36.00K |
| NetIncomeFromContinuingOperations | -35.48M | -31.48M | -13.88M | -21.71M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for FBRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|